There is a big issue in the NPO community now about how to value donated pharmaceuticals. To help the discussion along, I have three questions to help charities and their auditors process through what is the appropriate methodology.
I will pose three questions and ponder them for a moment. Each of the questions is really worth a long, extended conversation.
Should the medicine be valued at what was paid in the course of acquiring it or is there a bargain purchase?